Role of Pentoxifylline in Severe Alcoholic Hepatitis

Title: Role of Pentoxifylline in Severe Alcoholic Hepatitis

Authors: Rasmirekha Behera, Sushant Sethi

DOI: http://dx.doi.org/10.18535/jmscr/v4i9.30

Abstract

References

Corresponding Author

Abstract

AIM: Role of Pentoxifylline is compared with placebo in the treatment of Severe Alcoholic Hepatitis.

METHODS: Total 20 pts with severe alcoholic hepatitis (Maddrey DF ≥ 32) were included in the study.10 patients received pentoxifylline 400mg TDS for 4wks.And 10 patients received placebo for 4 wks. Baseline characteristics of the two groups were similar. Study was conducted for 4 wks.

RESULT: Statistical Analysis was done using student’s t test. The calculated t value found to be 25.01 at 18 df which indicates the difference between Placebo and Pentoxyfylline group is highly significant (P<0.001). Higher baseline Maddrey Discriminant Function was associated with increased mortality. But Pentoxifylline lowers the Maddrey Discriminant Function thus improves survival.

CONCLUSION: As compared to Placebo, Pentoxifylline reduce mortality, improved risk-benefit profile and lowers Maddrey Discriminant Function in patients with severe alcoholic hepatitis. Hence it is suggested that pentoxifylline is efficacious in treatment of severe alcoholic hepatitis.

KEYWORDS: Severe Alcoholic hepatitis, Pentoxifylline, Prednisolone, Maddrey discriminant function.

References

1. Hardison WG,Lee FI, Prognosis in the acute liver disease of the alcoholic patients .N Engl J Med 1966;275:61-66.

2. Leevy CM.Cirrhosis in alcoholics. Med Clinics North Am 1966;52:1445-51.

3. Zhang T,Li Y,Lai JP,Douglas SD,Metzger DS,O' Brien CP,Ho WZ.Alcohol potent-iates hepatitis C virus replicon expression. Hepatology.2003;38:57-65.{Pub Med}

4. Spahr L,Giostra E,Frossard JL,Bresson-Hadni S,Rubbia-Brandt L,Hadengue A, Soluble TNF-R1,but not tumor necrosis factor alfa,predicts the 3-month mortality in patients with alcoholic hepatitis.J Hepatol 2004;41:229-234{Pub Med}

5. McCullough AJ,O'Connor JF.Alcoholic liver disease:proposed recommendation for the American College of Gastroenterology. Am J Gastroenterol.1998;93:2022-2036. [PubMed]

6. Maddrey WC,Boitnott JK,Bedine MS,Weber FL Jr,Mezey E,White RI Jr.Corticosteroid therapy of alcoholic hepatitis.Gastroenterology 1978;75:193-6.

7. Sheth M.Riggs M.Patel T (2002)."Utility of the Mayo End-stage Liver Disease (MELD) scores in assessing prognosis of patients with alcoholic hepatitis" BMC gastroenterology2:2.

8. Akriviadis E,Botla R,Briggs W,Han S, Reynolds T,Shakil O (2000), "Pentoxifyl-line improves short term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial" Gastroenterology 119 (6):1637-48.

9. Christensen E.Alcoholic hepatitis-glucocorticoids or not?J Hepatol.2002;36: 547-548.[Pub Med]

10. Agarwal K,Kontorinis N,Dieterich DT. Alcoholic Hepatitis.Current Treat Options Gastroenterol.2004;7:451-458.[PubMed]

11. Haber PS,Warner R,Seth D,Gorwell MD,McCaughan GW.Pathogenesis and management of alcoholic hepatitis.J Gastroenterol Hepatol.2003;18:1332-1344. [PubMed]

12. Strieter R,Remick D,Ward P,Spengler RN,Lynch JP 3rd,Larrick J.Cellular and molecular regulation of tumor necrosis factor alfa production by pentoxifylline. Biochem Biophys Res Commun 1988; 155:1230-6.

13. Bienvenu J,Coulon L,Barbier Y,et al.Study of pentoxifylline induced modulation of TNF alfa and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model on whole blood.Nouv Rev Fr Hematol 1992;34 (suppl)S 1-3.

14. Raetsch C,Jia JD,Boigk G,Bauer M,Hahn EG, Riecken EO,Schuppan D. Pentoxifyl-line down regulates profibrogenic cytokinees and procollagen 1 expression in rat secondary billiary fibrosis. Gut. 2002; 50:241-247.

15. Lee KS,Cottam HB,Houglum K, Wasson DB,Carson D,Chojkier M.Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity. Am J Physiol.1997; 273:G1094-G1100.

16. Windmeier C, Gressner AM. Pharmacolo-gical aspects of pentoxifylline with emphasis on its inhibitory action on hepatic fibrogenesis. Gen Pharmacol. 1997; 29:181-196

Call For Paper Volume 12 Issue 12 December 2024

The JMSCR is accepting manuscripts for its coming issues to be Publish Volume 12 Issue 12 December 2024 the JMSCR invites authors to submit manuscripts Reporting original medical research, original article, research article, case report, systematic reviews, or educational Innovations for publication for the coming issues that will be released in Volume 12 Issue 12 December 2024. Types of manuscripts suitable for JMSCR include: Medical research, Clinical research Educational Innovation, Brief Report, Reviews on Teaching In keeping with high quality scholarship, Read More.....

https://jmscr.igmpublication.org/ems/index.php/jmscr/about/submissions

If any difficulty you can also submit to: This email address is being protected from spambots. You need JavaScript enabled to view it.

JMSCR Menu

Impact Factor SJIF 2024: 7.892

https://sjifactor.com/passport.php?id=1725

Crossref - DOI

Crossref - DOI Prefix: 10.18535/jmscr

Editorial Policy

Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not ..

Frequency of Publication

JMSCR is published as monthly journal with 12 issues per year. Special editions are also planned subjected to the scope and need....

Submission of Articles

Authors are invited to submit their research articles, review papers, Case Report properly formatted as per the author guidelines.........

Search

Abstract